GLYCOLIPID E-SELECTIN LIGANDS ON HUMAN GRANULOCYTES

人粒细胞上的糖脂 E-选择素配体

基本信息

  • 批准号:
    6053638
  • 负责人:
  • 金额:
    $ 32.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-02-15 至 2004-01-31
  • 项目状态:
    已结题

项目摘要

Inflammation involves extensive granulocyte extravasation from the blood into tissues at a site of infection or immunologic challenge. Adhesion molecules and complementary ligands on granulocytes and on the blood vessel wall endothelium control the extent and identity of granulocytes entering the tissue at a site of insult. E-selectin, expressed de novo on activated endothelial cells, is a selectin adhesion protein which mediates cell-cell adhesion early in this immune response by binding to leukocyte surface glycoconjugates. The identification of normal human granulocyte glycoconjugates responsible for E-selectin-mediated cell adhesion will be important to the understanding of inflammation in its many forms, and may offer novel avenues for inflammation control. Although several glycoconjugates which bind to selectins have been identified, the natural ligands for E-selectin on human granulocytes have yet to be fully elucidated. The applicants and others have obtained strong published and preliminary data indicating that glycosphingolipids on normal human neutrophils and eosinophils, not glycoproteins, are the most important legends for E-selectin, and that these glycosphingolipids may differ from those previously identified in cell lines such as HL-60. This proposal combines expertise from three laboratories in granulocyte cell adhesion under both static and physiologic flow conditions with glycosphingolipid glycobiology to evaluate the roles of normal human granulocyte glycosphingolipids in E-selectin binding and granulocyte function. Aim 1 tests the hypothesis that glycosphingolipids constitute major ligands for E-selectin on intact normal human neutrophils and eosinophils using cell adhesion assays and highly specific enzymes, antibodies, and glycoconjugate biosynthesis inhibitors. Aim 2 uses methods for glycosphingolipid extraction, resolution and functional analysis to isolate and identify glycosphingolipids from normal peripheral blood neutrophils and eosinophils capable of specific binding to E-selectin. TLC analysis, antibodies, specific enzymes, and matrix assisted laser desorption ionization mass spectroscopy will be used to elucidate and characterize the structures of these glycosphingolipids. Aim 3 will test glycosphingolipids on intact cells, and glycosphingolipids identified from Aim 2, for their roles in granulocyte cell adhesion under static conditions and physiological flow, and will allow us to test whether these glycosphingolipids are the natural ligands for E-selectin on normal human granulocytes. Knowledge gained from these studies will advance the design of improved anti-inflammatory drugs, and our understanding of the physiological roles of glycosphingolipids in leukocyte adhesion.
炎症包括感染或免疫挑战部位的大量粒细胞从血液渗入组织。粒细胞和血管壁内皮细胞上的黏附分子和互补配体控制着粒细胞在损伤部位进入组织的程度和特性。E-选择素在激活的内皮细胞上从头表达,是一种选择素黏附蛋白,在免疫反应早期通过与白细胞表面的糖偶联物结合来介导细胞与细胞的黏附。鉴定与E-选择素介导的细胞黏附有关的正常人类粒细胞糖偶联物对于理解多种形式的炎症具有重要意义,并可能为炎症控制提供新的途径。虽然已经鉴定了几种与选择素结合的糖偶联物,但人粒细胞上E-选择素的天然配体仍未完全阐明。申请人和其他人已经获得了强有力的已发表的初步数据,表明E-选择素最重要的传说是正常人中性粒细胞和嗜酸性粒细胞上的鞘糖脂,而不是糖蛋白,这些鞘糖脂可能不同于之前在HL-60等细胞系中发现的那些。这项建议结合了三个实验室在静态和生理流动条件下粒细胞黏附方面的专业知识和鞘糖脂糖生物学,以评估正常人粒细胞鞘糖脂在E-选择素结合和粒细胞功能中的作用。目的1利用细胞黏附实验和高度特异性的酶、抗体和糖结合生物合成抑制剂,验证神经鞘糖脂是正常中性粒细胞和嗜酸性粒细胞上E-选择素的主要配体的假说。目的利用鞘糖脂的提取、拆分和功能分析方法,从正常人外周血中性粒细胞和嗜酸性粒细胞中分离鉴定能与E-选择素特异性结合的鞘糖脂。将使用TLC分析、抗体、特定酶和基质辅助激光解吸电离质谱仪来阐明和表征这些糖鞘糖脂的结构。AIM 3将测试完整细胞上的神经鞘糖脂,以及从AIM 2中鉴定的神经鞘糖脂,以确定它们在静态条件和生理流动下对粒细胞黏附的作用,并将允许我们测试这些神经鞘糖脂是否是正常人粒细胞上E-选择素的天然配体。从这些研究中获得的知识将促进改进抗炎药物的设计,以及我们对神经鞘糖脂在白细胞黏附中的生理作用的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bruce S Bochner其他文献

Bruce S Bochner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bruce S Bochner', 18)}}的其他基金

Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cells
利用 Siglec-6 将靶向抗过敏药物输送到人体肥大细胞中
  • 批准号:
    10194041
  • 财政年份:
    2021
  • 资助金额:
    $ 32.04万
  • 项目类别:
Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cells
利用 Siglec-6 将靶向抗过敏药物输送到人体肥大细胞中
  • 批准号:
    10368109
  • 财政年份:
    2021
  • 资助金额:
    $ 32.04万
  • 项目类别:
Using siglecs and their ligands to treat allergic diseases SALTAD
使用siglecs及其配体治疗过敏性疾病SALTAD
  • 批准号:
    10331722
  • 财政年份:
    2018
  • 资助金额:
    $ 32.04万
  • 项目类别:
Defining Siglec-6 and Siglec-8 function on effector cells of allergic diseases
定义 Siglec-6 和 Siglec-8 对过敏性疾病效应细胞的功能
  • 批准号:
    10097994
  • 财政年份:
    2018
  • 资助金额:
    $ 32.04万
  • 项目类别:
Core A Admin
核心A管理员
  • 批准号:
    10331723
  • 财政年份:
    2018
  • 资助金额:
    $ 32.04万
  • 项目类别:
Core A Admin
核心A管理员
  • 批准号:
    10097991
  • 财政年份:
    2018
  • 资助金额:
    $ 32.04万
  • 项目类别:
Using siglecs and their ligands to treat allergic diseases SALTAD
使用siglecs及其配体治疗过敏性疾病SALTAD
  • 批准号:
    10097976
  • 财政年份:
    2018
  • 资助金额:
    $ 32.04万
  • 项目类别:
Defining Siglec-6 and Siglec-8 function on effector cells of allergic diseases
定义 Siglec-6 和 Siglec-8 对过敏性疾病效应细胞的功能
  • 批准号:
    10331725
  • 财政年份:
    2018
  • 资助金额:
    $ 32.04万
  • 项目类别:
Human mast cell and tissue acquisition core
人类肥大细胞和组织采集核心
  • 批准号:
    10331724
  • 财政年份:
    2018
  • 资助金额:
    $ 32.04万
  • 项目类别:
Human mast cell and tissue acquisition core
人类肥大细胞和组织采集核心
  • 批准号:
    10097992
  • 财政年份:
    2018
  • 资助金额:
    $ 32.04万
  • 项目类别:

相似海外基金

The formation and degradation of neutrophil and eosinophil extracellular traps in otitis media
中耳炎中中性粒细胞和嗜酸性粒细胞胞外陷阱的形成和降解
  • 批准号:
    23K08953
  • 财政年份:
    2023
  • 资助金额:
    $ 32.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of eosinophil cationic proteins in cardiac hypertrophy
嗜酸性粒细胞阳离子蛋白在心脏肥大中的作用
  • 批准号:
    10735136
  • 财政年份:
    2023
  • 资助金额:
    $ 32.04万
  • 项目类别:
Role of GATA2-RPN1 intergenic region common variants in eosinophil/basophil regulation
GATA2-RPN1基因间区域常见变异在嗜酸性粒细胞/嗜碱性粒细胞调节中的作用
  • 批准号:
    23K06375
  • 财政年份:
    2023
  • 资助金额:
    $ 32.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
12th Biennial Symposium of the International Eosinophil Society, Inc. (IES)
国际嗜酸性粒细胞学会 (IES) 第 12 届双年研讨会
  • 批准号:
    10682801
  • 财政年份:
    2023
  • 资助金额:
    $ 32.04万
  • 项目类别:
Anti-eosinophil Gene Therapy for Eosinophilic Esophagitis
抗嗜酸性粒细胞基因治疗嗜酸性粒细胞性食管炎
  • 批准号:
    10481279
  • 财政年份:
    2022
  • 资助金额:
    $ 32.04万
  • 项目类别:
The regulatory mechanism of sympathetic nerves on eosinophil-associated micr o-inflammation in animals with IBS
交感神经对IBS动物嗜酸性粒细胞相关微炎症的调节机制
  • 批准号:
    22K15656
  • 财政年份:
    2022
  • 资助金额:
    $ 32.04万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Basic research on eosinophil subsets to aim a precision medicine for severe eosinophilic asthma
嗜酸性粒细胞亚群的基础研究旨在针对严重嗜酸性粒细胞哮喘的精准治疗
  • 批准号:
    21K08218
  • 财政年份:
    2021
  • 资助金额:
    $ 32.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of eosinophil-associated heart disease
嗜酸性粒细胞相关心脏病的机制
  • 批准号:
    10117454
  • 财政年份:
    2021
  • 资助金额:
    $ 32.04万
  • 项目类别:
Development of a Treatment for Eosinophil-Mediated Allergic Inflammatory Diseases Utilizing a Neutralizing Agent Targeting Eosinophil Granule Major Basic Protein
利用针对嗜酸性粒细胞颗粒主要碱性蛋白的中和剂开发治疗嗜酸性粒细胞介导的过敏性炎症疾病的方法
  • 批准号:
    10401936
  • 财政年份:
    2021
  • 资助金额:
    $ 32.04万
  • 项目类别:
Function of the IL-18-IL-18R1-IFN-T2 Cytokine Eosinophil Axis in Asthma
IL-18-IL-18R1-IFN-T2 细胞因子嗜酸性粒细胞轴在哮喘中的功能
  • 批准号:
    10311950
  • 财政年份:
    2021
  • 资助金额:
    $ 32.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了